Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

U.S. FDA approves GlaxoSmithKline's blood cancer drug

Published 06/08/2020, 03:00
Updated 06/08/2020, 03:40
© Reuters. FILE PHOTO: Outbreak of the coronavirus disease (COVID-19) in London

© Reuters. FILE PHOTO: Outbreak of the coronavirus disease (COVID-19) in London

(Reuters) - The U.S. Food and Drug Administration on Wednesday approved GlaxoSmithKline's (L:GSK) experimental treatment for a common form of blood cancer.

GSK's belantamab mafodotin, or BLENREP, was approved for treating adults with relapsed and refractory multiple myeloma who no longer respond to treatment with an immunomodulatory agent, the drugmaker said in a statement.

Multiple myeloma is the second most common form of blood cancer in the U.S. and is generally considered treatable, but not curable.

A U.S. FDA panel had earlier raised safety concerns about the drug causing deposits to gather on the cornea in the eyes, but later voted in its favor saying the benefits of the treatment outweigh the risks.

Approval for belantamab mafodotin, a rival to Johnson & Johnson (N:JNJ) and Genmab 's (CO:GMAB) Darzalex treatment, is seen as important for GSK's growing oncology portfolio.

Last month, a panel of the European Medicines Agency (EMA) also recommended approving the drug.

© Reuters. FILE PHOTO: A GSK logo is seen at the GSK research centre in Stevenage

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.